Difference between revisions of "Busulfan (Myleran)"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 11: | Line 11: | ||
*[[Acute promyelocytic leukemia]] | *[[Acute promyelocytic leukemia]] | ||
*[[Bone cancer]] | *[[Bone cancer]] | ||
| + | *[[CNS lymphoma]] | ||
*[[Transplant conditioning regimens]] | *[[Transplant conditioning regimens]] | ||
| Line 31: | Line 32: | ||
[[Category:Acute promyelocytic leukemia medications]] | [[Category:Acute promyelocytic leukemia medications]] | ||
[[Category:Bone cancer medications]] | [[Category:Bone cancer medications]] | ||
| + | [[Category:Central nervous system (CNS) lymphoma medications]] | ||
[[Category:Transplant medications]] | [[Category:Transplant medications]] | ||
[[Category:Drugs FDA approved in 1954]] | [[Category:Drugs FDA approved in 1954]] | ||
Revision as of 02:36, 27 February 2015
Also known as Busulfex.
General information
Class/mechanism: Bifunctional alkylating agent which produces guanine-adenine intrastrand crosslinks, inducing apoptosis.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Busulfan (Myleran) patient drug information (Chemocare)[3]
- Busulfan (Myleran) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 6/26/1954: Initial FDA approval